Laboratorio Reig Jofre, S.a. · BME:RJF
Laboratorio Reig Jofre — Reig Jofre — FY2022 Earnings Presentation
16 slides from Laboratorio Reig Jofre's earnings presentation, 2023
Slide 1: 4Q Results, Fourth Quarter of 2022
4Q RESULTS Fourth Quarter of 2022
Slide 2: Table of Contents
TABLE OF CONTENTS 01 2022 Q4 RESULTS 02 INCOME STATEMENT AND BALANCE SHEET 03 2022 CLOSING EVALUATION 04 RJF SHARE PERFORMANCE
Slide 3: Q4 2022 Results
(3) Nn = —! =) Nn Lu [a
Slide 4: 2022 Fourth Quarter Results
2022 FOURTH QUARTER RESULTS REIG JOFRE had 15% growth in revenue and 11% growth in EBITDA at the end of 2022 The sales figures for the year 2022 reached €271 million, exceeding the same period in 2021 by SALES + 15% 15%. The hospital product division, Pharmaceutical Technologies, leads this growth
Slide 5: Revenues by Business Unit
REVENUES BY BUSINESS UNIT PHARMACEUTICAL SPECIALITY CONSUMER TECHNOLOGIES PHARMACARE HEALTHCARE Antibiotics Osteoarticular OTC Injectables/Lyophilisates Dermatology Energy Stress and sleep 125.0 65.7 Weight 80.4 management 46% million euros 30% million euros 24% Beauty million euros +20% +7% +16%
Slide 6: Sales by Geographical Area
SALES BY GEOGRAPHICAL AREA Rest of Rest of SPAIN EUROPE WORLD 44% 47% 9% €118.6M €127.2M €25.4M Spain European 44% Union + 12% + 25% - 13% 41% The Spanish market confirmed acceleration compared with the first quarter, in which it grew by 6%. The increased demand for antibiotics, the gradual increa
Slide 7: Income Statement and Balance Sheet
INCOME STATEMENT AND BALANCE SHEET 02
Slide 8: Income Statement
INCOME STATEMENT 2022/2021 Outlook Q4 2022 The growth in the sales figure of 15% is associated with a gross margin of 58.3%, significantly below the previous year (61.3%) due to 000's miles euros 31/12/2022 31/12/2021 the increasing pressure on costs and the greater weight of the income from antib
Slide 9: Balance Sheet: Investment and R&D Capitalisation
BALANCE SHEET 13,4 Q4 2022 2022 INVESTMENT 000's miles euros euros 31/12/2022 31/12/2022 31/12/2021 31/12/2021 million euros ACTIVO ASSETS Fondo de comercio Goodwill 28.972 28.972 29.843 29,843 Otros Other activos intangibles intangible assets 70.893 70,893 77.727 77,727 R&D Fixed assets material In
Slide 10: Balance Sheet: Net Financial Debt
BALANCE SHEET Q4 2022 NET FINANCIAL DEBT Debt|EBITDA miles euros 000's euros 31/12/2022 31/12/2021 PATRIMONIO EQUITY NETO Y PASIVO AND LIABILITIES 2022 62,3 2022 TOTAL NET EQUITY NETO 194,553 188,514 year- year- 2.0 PATRIMONIO 194.553 188.514 million euros end end Subvenciones Subsidies 3,695 3.695
Slide 11: Outlook
= O oO —_ - =) oO 2022
Slide 12: Close of 2022 and 2023 Outlook
Close of 2022 REIG JOFRE confirms at the end of 2022 the trend of growth in sales and results of the first quarters, achieving a 15% increase in revenue, with an EBITDA that exceeds €30 million. & 2023 Outlook In a favourable market context, and with the new injectable plant in Barcelona in the capa
Slide 13: RJF Share Performance
RJF SHARE PERFORMANCE ey REIGQIJOFRE ~=
Slide 14: RJF Share Performance 2022
RJF SHARE PERFORMANCE 2022 MARKET CAPITALISATION €172 million Data as at 31 December 2022 SCRIP DIVIDEND 2022 4,00 • Remuneration €0.04/right cash or shares Close • 97.2% of shareholders opt for shares 3,50 31/12/21 • 990,533 shares issued (1.26% capital) 3,00 €3.26 2,50 AVERAGE DAILY VOLUME 2,00 •
Slide 15: Links and Extra Information
LINKS AND EXTRA INFORMATION LATEST NEWS RESULTS WEBCAST SUBSCRIPTION CENTRE www.reigjofre.com/en/news http://www.reigjofre.com/en/investors/webcasts https://reigjofre.com/en/news/subscription-center/
Slide 16: Q4 Thank you
Q4 Thank you Av. de les Flors 08970 Sant Joan Despí, Barcelona, Spain Tel. +34 93 480 67 10 www.reigjofre.com Investor Relations investors@reigjofre.com